All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
7th European CAR T-cell Meeting congress coverage
Bookmark this article
Stay up to date with the latest developments in multiple myeloma with our live social media coverage from the 7th European CAR T-cell Meeting, February 6–8, 2025, Strasbourg, FR.
CONGRESS | #CART25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) February 8, 2025
Niels van de Donk @amsterdamumc provides an overview of bispecific antibody therapies for patients with multiple myeloma. They present results from several key studies and discuss potential future directions.#myeloma #mmsm #MedicalCongress pic.twitter.com/piGjqf3vsU
CONGRESS | #CART25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) February 8, 2025
Vladan Vucinic @UniLeipzig discusses results from several real-world studies of commercial CAR T-cell therapies for the treatment of patients with multiple myeloma. They highlight factors associated with outcomes, and raise the need for clinical… pic.twitter.com/XW41w0HN16
CONGRESS | #CART25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) February 8, 2025
Carlos Fernández de Larrea @fdezdelarrea @hospitalclinic highlights results from a study of ARI0002h in patients with R/R multiple myeloma, and discusses the potential impact of academic point-of-care CAR T-cell manufacturing on access to CAR… pic.twitter.com/WAoC5w0Psf
Your opinion matters
2 votes - 47 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox